Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

RSS icon
cardiovascular heart diagnostics

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.

FDA finalizes new heart warnings for COVID-19 vaccines

The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines.

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

American College of Cardiology now supports early use of medication to treat obesity

The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions. 

cannabis use disorder marijuana joint weed smoking

Cannabis is bad for the heart—should the risk be taken more seriously?

Use of the drug more than doubles a person's risk of dying from heart disease, according to a new analysis of 24 different studies. In a separate editorial, two physicians shared their concerns and highlighted the importance of discussing these risks with patients.

Thumbnail

Updated: Dexcom recalls more than 700K CGM receivers over safety issues—dozens of adverse events reported

There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts.

Janet Wei, MD, Erika J. Glazer Chair in Women’s Cardiovascular Research, Education and Innovation at the Smidt Heart Institute at Cedars-Sinai Hospital, explains the key differences between men and women in cardiovascular disease presentations and disease progression. She said heart disease its the number one cause of death in women and the guidelines cannot be a one size fits all document lumping men and women together, they really need to separate out specific details for women.

Cardiology societies should develop separate guidelines for treating female heart patients

Janet Wei, MD, examined the key differences between men and women when it comes to cardiovascular disease. These differences, she said, highlight why female patients need their very own treatment guidelines.

merger acquisition M&A business

Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Displaying 49 - 56 of 1070
Design by Adaptive Theme